Let’s partner to transform medicine—
and succeed together

At Assembly Bio, we take pride in the ingenuity, agility and rigor we apply to the scientific research we do. As a result, we’ve built some of the most cutting-edge drug discovery platforms in biopharma today. Our R&D effort is strong. It can be even stronger with the right academic and corporate partnerships in place.

Assembly Bio has a license and collaboration agreement with BeiGene to develop and commercialize our HBV product candidates vebicorvir (VBR, ABI-H0731), and ABI-H3733 in China, including Hong Kong, Macau and Taiwan.

Assembly Bio and Arbutus Biopharma have a clinical collaboration agreement to evaluate a triple combination treatment with Assembly Bio’s lead HBV core inhibitor VBR in combination with Arbutus’ proprietary GalNAc delivered RNAi compound AB-729 and standard-of-care therapy for the treatment of patients with chronic HBV infection.1

1While Assembly Bio has discontinued further development of first-generation core inhibitor, vebicorvir (VBR), a Phase 2 triple combination study conducted in collaboration with Arbutus Biopharma evaluating VBR + NrtI + Arbutus’ investigational RNAi is ongoing.

If your organization is interested in collaborating with Assembly Bio
on a potential research and development venture, please
contact us at: BD@assemblybio.com.